Advances in glucocorticoid-induced osteoporosis

Current Rheumatology Reports

Volumn 13, Issue 3, 2011, Pages 233-240

  Den Uyl, Debby ^a   Bultink, Irene E M ^a   Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE METABOLISM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENTERITIS; FRACTURE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; INCIDENCE; MOLECULAR MECHANICS; OSTEOLYSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

BONE AND BONES; BONE DENSITY; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 79957526871     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0173-y     Document Type: Article

References (51)

1. JA Kanis H Johansson A Oden, et al. 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 893 899 15125788 10.1359/JBMR.040134 (Pubitemid 41103445)
2. TP van Staa HG Leufkens C Cooper 2002 The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis Osteoporos Int 13 777 787 12378366 10.1007/s001980200108 (Pubitemid 36336722)
3. B Gudbjornsson UI Juliusson FV Gudjonsson 2002 Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice Ann Rheum Dis 61 32 36 11779755 10.1136/ard.61.1.32 1:CAS:528:DC%2BD38XntFanug%3D%3D (Pubitemid 34074836)
4. K Natsui K Tanaka M Suda, et al. 2006 High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass Osteoporos Int 17 105 108 15886861 10.1007/s00198-005-1923-3 1:CAS:528:DC%2BD2MXhtlWkt7rI (Pubitemid 41798034)
5. JD Adachi KG Saag PD Delmas, et al. 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial Arthritis Rheum 44 202 211 11212161 10.1002/1529-0131(200101)44:1<202::AID- ANR27>3.0.CO;2-W 1:CAS:528:DC%2BD3MXht1yiu7o%3D (Pubitemid 32113136)
6. S Cohen RM Levy M Keller, et al. 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309 2318 10555025 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K 1:CAS:528:DyaK1MXnvVShsLs%3D (Pubitemid 30333410)
7. Reid DM, Devogelaer JP, Saag K, et al.: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-63. In this double-blind study, zoledronic acid was compared with risedronate in the prevention of GIOP in men and women receiving treatment with prednisolone. Zoledronic acid increased BMD of the spine more than risedronate and showed a faster inhibitory effect on bone markers. Therefore, this study showed that zoledronic acid is an important additional treatment option for GIOP.
8. C Cooper C Coupland M Mitchell 1995 Rheumatoid arthritis, corticosteroid therapy and hip fracture Ann Rheum Dis 54 49 52 7880122 10.1136/ard.54.1.49 1:STN:280:DyaK2M7osFynsQ%3D%3D
9. TP van Staa P Geusens HA Pols C de Laet HG Leufkens C Cooper 2005 A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids QJM 98 191 198 15728400 10.1093/qjmed/hci029 (Pubitemid 40361316)
10. TP van Staa 2006 The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis Calcif Tissue Int 79 129 137 16969593 10.1007/s00223-006-0019-1 1:CAS:528:DC%2BD28XpvFalsbk%3D (Pubitemid 44440440)
11. F De Vries M Bracke HG Leufkens, et al. 2007 Fracture risk with intermittent high-dose oral glucocorticoid therapy Arthritis Rheum 56 208 214 17195223 10.1002/art.22294 (Pubitemid 46106193)
12. JA Kanis F Borgstrom C De Laet, et al. 2005 Assessment of fracture risk Osteoporos Int 16 581 589 15616758 10.1007/s00198-004-1780-5 (Pubitemid 40897454)
13. WF Lems 2007 Bisphosphonates and glucocorticoids: effects on bone quality Arthritis Rheum 56 3518 3522 17968935 10.1002/art.22975 1:CAS:528: DC%2BD2sXhsVSkt73F (Pubitemid 350100684)
14. TP van Staa HG Leufkens L Abenhaim, et al. 2000 Use of oral corticosteroids in the United Kingdom QJM 93 105 111 10700481 10.1093/qjmed/93.2.105 (Pubitemid 30098773)
15. TP van Staa RF Laan IP Barton, et al. 2003 Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 3224 3229 14613287 10.1002/art.11283 (Pubitemid 37409336)
16. LI McKay JA Cidlowski 1998 Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism Mol Endocrinol 12 45 56 9440809 10.1210/me.12.1.45 1:CAS:528:DyaK1cXhvFSqsA%3D%3D (Pubitemid 28124778)
17. BM Vayssiere S Dupont A Choquart, et al. 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo Mol Endocrinol 11 1245 1255 9259316 10.1210/me.11.9.1245 1:CAS:528:DyaK2sXkvFajuro%3D (Pubitemid 28041332)
18. F Buttgereit RH Straub M Wehling GR Burmester 2004 Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action Arthritis Rheum 50 3408 3417 15529366 10.1002/art.20583 1:CAS:528: DC%2BD2cXhtVOqtrvI (Pubitemid 39488664)
19. RS Weinstein RL Jilka AM Parfitt SC Manolagas 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone J Clin Invest 102 274 282 9664068 10.1172/JCI2799 1:CAS:528:DyaK1cXkslOktrc%3D (Pubitemid 28335186)
20. CA O'Brien D Jia LI Plotkin, et al. 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength Endocrinology 145 1835 1841 14691012 10.1210/en.2003-0990 (Pubitemid 38402392)
21. Y Liu A Porta X Peng, et al. 2004 Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k J Bone Miner Res 19 479 490 15040837 10.1359/JBMR.0301242 1:CAS:528:DC%2BD2cXisFCrt7k%3D (Pubitemid 38787404)
22. SI Yun HY Yoon SY Jeong YS Chung 2009 Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta J Bone Miner Metab 27 140 148 19066717 10.1007/s00774-008-0019-5 1:CAS:528:DC%2BD1MXitFKmt7g%3D
23. K Ohnaka M Tanabe H Kawate H Nawata R Takayanagi 2005 Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts Biochem Biophys Res Commun 329 177 181 15721290 10.1016/j.bbrc.2005.01.117 1:CAS:528:DC%2BD2MXhsFSisrg%3D (Pubitemid 40255437)
24. FS Wang JY Ko DW Yeh HC Ke HL Wu 2008 Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss Endocrinology 149 1793 1801 18174290 10.1210/en.2007-0910 1:CAS:528:DC%2BD1cXktVeqs7k%3D (Pubitemid 351468308)
25. RC Pereira AM Delany E Canalis 2002 Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression Bone 30 685 691 11996905 10.1016/S8756-3282(02)00687-7 1:CAS:528:DC%2BD38Xjtl2ltLc%3D (Pubitemid 34467988)
26. JS Butler JM Queally BM Devitt, et al. 2010 Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation BMC Musculoskelet Disord 11 210 20843343 10.1186/1471-2474-11- 210
27. XM Shi HC Blair X Yang JM McDonald X Cao 2000 Tandem repeat of C/EBP binding sites mediates PPARgamma2 gene transcription in glucocorticoid-induced adipocyte differentiation J Cell Biochem 76 518 527 10649448 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M 1:CAS:528:DC%2BD3cXhtValsb4%3D (Pubitemid 30078460)
28. I Carcamo-Orive A Gaztelumendi J Delgado, et al. 2010 Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk J Bone Miner Res 25 2115 2125 20499359 10.1002/jbmr.120 1:CAS:528:DC%2BC3cXhtlaktbzF
29. LC Hofbauer F Gori BL Riggs, et al. 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis Endocrinology 140 4382 4389 10499489 10.1210/en.140.10.4382 1:CAS:528:DyaK1MXmtFGrurw%3D (Pubitemid 30666099)
30. T Kondo R Kitazawa A Yamaguchi S Kitazawa 2008 Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels J Cell Biochem 103 1 335 345 17516544 10.1002/jcb.21414 1:CAS:528: DC%2BD1cXnsVGmtQ%3D%3D
31. HJ Kim H Zhao H Kitaura, et al. 2006 Glucocorticoids suppress bone formation via the osteoclast J Clin Invest 116 2152 2160 16878176 10.1172/JCI28084 1:CAS:528:DC%2BD28XnvF2mtrc%3D (Pubitemid 44162324)
32. E Canalis G Mazziotti A Giustina JP Bilezikian 2007 Glucocorticoid- induced osteoporosis: pathophysiology and therapy Osteoporos Int 18 1319 1328 17566815 10.1007/s00198-007-0394-0 1:CAS:528:DC%2BD2sXhtVagurrN (Pubitemid 47389469)
33. Gillespie LD, Robertson MC, Gillespie WJ, et al.: Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009, (2):CD007146.
34. P Lips 2009 Relative value of 25(OH)D and 1, 25(OH)2D measurements J Bone Miner Res 22 1668 1671 10.1359/jbmr.070716 (Pubitemid 351235133)
35. BM Tang GD Eslick C Nowson C Smith A Bensoussan 2007 Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis Lancet 370 657 666 17720017 10.1016/S0140-6736(07)61342-7 1:CAS:528:DC%2BD2sXpsFWrsbc%3D (Pubitemid 47285316)
36. JA Kanis N Burlet C Cooper, et al. 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 18266020 10.1007/s00198-008-0560-z 1:STN:280:DC%2BD1c3itFekuw%3D%3D
37. S Amin MP Lavalley RW Simms DT Felson 2002 The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression J Bone Miner Res 17 1512 1526 12162505 10.1359/jbmr.2002.17.8. 1512 1:CAS:528:DC%2BD38XmsVWktbc%3D (Pubitemid 34803834)
38. DM Reid RA Hughes RF Laan, et al. 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15 1006 1013 10841169 10.1359/jbmr.2000.15.6. 1006 1:CAS:528:DC%2BD3cXktFKhtbs%3D (Pubitemid 30350063)
39. KG Saag R Emkey TJ Schnitzer, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group N Engl J Med 339 292 299 9682041 10.1056/NEJM199807303390502 1:CAS:528:DyaK1cXlsVOitr4%3D (Pubitemid 28366417)
40. SA Stoch KG Saag M Greenwald, et al. 2009 Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a randomized, placebo-controlled clinical trial J Rheumatol 36 1705 1714 19487264 10.3899/jrheum.081207 1:CAS:528:DC%2BD1MXhtV2hu7nI
41. S Wallach S Cohen DM Reid, et al. 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 277 285 11000340 10.1007/s002230001146 1:CAS:528: DC%2BD3cXntlOlu74%3D
42. A Fahrleitner-Pammer JC Piswanger-Soelkner TR Pieber, et al. 2009 Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial J Bone Miner Res 24 1335 1344 19257824 10.1359/jbmr.090216 1:CAS:528: DC%2BD1MXosFCkt7k%3D
43. W Yao Z Cheng A Pham, et al. 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization Arthritis Rheum 58 3485 3497 18975341 10.1002/art.23954 1:CAS:528:DC%2BD1cXhsV2hs7bJ
44. KG Saag E Shane S Boonen, et al. 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2028 2039 18003959 10.1056/NEJMoa071408 1:CAS:528:DC%2BD2sXhtlWis7rP (Pubitemid 350106710)
45. Saag KG, Zanchetta JR, Devogelaer JP, et al.: Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-55. This article provides the extended results of the randomized controlled trial comparing the anabolic drug teriparatide with the antiresorptive drug alendronate, including data on fracture risk. After 36 months, teriparatide was superior to alendronate in preventing bone loss and in reducing fracture risk in individuals with GIOP.
46. BL Langdahl G Rajzbaum F Jakob, et al. 2009 Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS) Calcif Tissue Int 85 484 493 19823760 10.1007/s00223-009-9299-6 1:CAS:528:DC%2BD1MXhsFSrt7fN
47. RS Weinstein RL Jilka M Almeida PK Roberson SC Manolagas 2010 Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice Endocrinology 151 2641 2649 20410195 10.1210/en.2009-1488 1:CAS:528:DC%2BC3cXnsVyqt7w%3D
48. Grossman JM, Gordon R, Ranganath VK, et al.: American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010,62:1515-26. In this article, the new American College of Rheumatology recommendations are presented, offering an up-to-date guideline for GIOP prevention and treatment.
49. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ: Adherence and profile of non-persistence in patients treated for osteoporosis - a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2010 Sep 14 (Epub ahead of print). Although more knowledge was gained in treatment options for GIOP, this study showed that persistence to osteoporosis medication still is an important factor in daily practice.
50. EW de Bekker-Grob ML Essink-Bot WJ Meerding BW Koes EW Steyerberg 2009 Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment Pharmacoeconomics 27 211 219 19354341 10.2165/00019053-200927030-00004
51. ED Newman CK Matzko TP Olenginski, et al. 2006 Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year Osteoporos Int 17 1428 1434 16865312 10.1007/s00198-006-0149-3 1:STN:280:DC%2BD28vktFOrtg%3D%3D (Pubitemid 44127331)